Horizon Therapeutics Public Limited (NASDAQ:HZNP) Shares Sold by Creative Planning
Horizon Therapeutics Public Limited (NASDAQ:HZNP) Shares Sold by Creative Planning
Creative Planning reduced its stake in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) by 18.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,068 shares of the biopharmaceutical company's stock after selling 1,556 shares during the quarter. Creative Planning's holdings in Horizon Therapeutics Public were worth $437,000 at the end of the most recent quarter.
根据创意策划最近提交给美国证券交易委员会(美国证券交易委员会)的文件,在第三季度,创意策划将其在地平线治疗公共有限公司(HZNP-GET评级)的股份减少了18.0%。该机构投资者在本季度出售了1,556股后,持有这家生物制药公司的7068股股票。截至最近一个季度末,创意规划公司在Horizon Treateutics Public持有的股份价值43.7万美元。
Several other hedge funds and other institutional investors have also recently bought and sold shares of HZNP. Samalin Investment Counsel LLC acquired a new position in Horizon Therapeutics Public during the first quarter worth about $41,000. CoreCap Advisors LLC acquired a new position in shares of Horizon Therapeutics Public in the second quarter valued at approximately $33,000. Allworth Financial LP raised its position in shares of Horizon Therapeutics Public by 936.7% in the third quarter. Allworth Financial LP now owns 622 shares of the biopharmaceutical company's stock valued at $38,000 after buying an additional 562 shares during the last quarter. Stonebridge Capital Advisors LLC raised its position in shares of Horizon Therapeutics Public by 550.0% in the first quarter. Stonebridge Capital Advisors LLC now owns 650 shares of the biopharmaceutical company's stock valued at $68,000 after buying an additional 550 shares during the last quarter. Finally, Covestor Ltd raised its position in shares of Horizon Therapeutics Public by 152.9% in the first quarter. Covestor Ltd now owns 860 shares of the biopharmaceutical company's stock valued at $91,000 after buying an additional 520 shares during the last quarter. 91.01% of the stock is currently owned by institutional investors and hedge funds.
其他几家对冲基金和其他机构投资者最近也买卖了HZNP的股票。萨马林投资顾问有限责任公司在第一季度收购了Horizon治疗公共公司的一个新头寸,价值约41,000美元。CoreCap Advisors LLC在第二季度收购了Horizon Treateutics Public的新股份,价值约3.3万美元。Allworth Financial LP在第三季度将其在Horizon Treateutics Public的股票头寸提高了936.7%。Allworth Financial LP现在拥有这家生物制药公司622股股票,价值3.8万美元,此前在上个季度又购买了562股。第一季度,Stonebridge Capital Advisors LLC将其在Horizon Treateutics Public的股票持有量提高了550.0%。Stonebridge Capital Advisors LLC现在拥有650股这家生物制药公司的股票,价值6.8万美元,在上个季度又购买了550股。最后,Covestor有限公司在第一季度将其在Horizon Treateutics Public的股票持有量提高了152.9%。Covestor Ltd现在拥有这家生物制药公司860股股票,价值91,000美元,此前在上个季度又购买了520股。91.01%的股票目前由机构投资者和对冲基金持有。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
HZNP has been the subject of a number of analyst reports. BMO Capital Markets lowered shares of Horizon Therapeutics Public from an "outperform" rating to a "market perform" rating in a research report on Tuesday, December 13th. SVB Leerink lowered shares of Horizon Therapeutics Public from an "outperform" rating to a "market perform" rating and upped their price target for the stock from $88.00 to $116.50 in a research report on Tuesday, December 13th. Wells Fargo & Company lowered shares of Horizon Therapeutics Public from an "overweight" rating to an "equal weight" rating and dropped their price target for the stock from $118.00 to $116.50 in a research report on Monday, December 12th. TheStreet raised shares of Horizon Therapeutics Public from a "c+" rating to a "b-" rating in a research report on Tuesday, November 22nd. Finally, HC Wainwright began coverage on shares of Horizon Therapeutics Public in a research note on Tuesday, November 1st. They set a "neutral" rating and a $74.00 price objective for the company. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $111.42.
HZNP一直是多份分析师报告的主题。在12月13日星期二的一份研究报告中,BMO Capital Markets将Horizon Treateutics Public的股票评级从“跑赢大盘”下调至“市场表现”。SVB Leerink在12月13日(星期二)的一份研究报告中将Horizon Treateutics Public的股票评级从“跑赢大盘”下调至“市场表现”,并将其股票目标价从88美元上调至116.50美元。在12月12日星期一的一份研究报告中,富国银行将Horizon Treateutics Public的股票评级从“增持”下调至“持平”评级,并将其股票目标价从118.00美元下调至116.50美元。在11月22日星期二的一份研究报告中,华尔街将Horizon治疗公共公司的股票评级从“c+”上调至“b-”。最后,HC Wainwright在11月1日星期二的一份研究报告中开始报道Horizon治疗公共公司的股票。他们为该公司设定了“中性”评级和74.00美元的目标价。8名研究分析师对该股的评级为持有,4名分析师对该股的评级为买入。根据MarketBeat的数据,该公司的平均评级为持有,平均目标价为111.42美元。
Insider Activity at Horizon Therapeutics Public
Horizon治疗公众的内幕活动
Horizon Therapeutics Public Price Performance
Horizon治疗公司的公共价格表现
NASDAQ HZNP opened at $109.68 on Friday. The company has a 50 day simple moving average of $109.07 and a 200-day simple moving average of $82.36. The company has a debt-to-equity ratio of 0.51, a current ratio of 3.96 and a quick ratio of 3.74. The firm has a market capitalization of $24.86 billion, a price-to-earnings ratio of 44.95, a price-to-earnings-growth ratio of 1.70 and a beta of 1.15. Horizon Therapeutics Public Limited has a 52-week low of $57.84 and a 52-week high of $117.49.
纳斯达克HZNP上周五开盘报109.68美元。该公司的50日简单移动均线切入位在109.07美元,200日简单移动均线切入位在82.36美元。该公司的债务权益比为0.51,流动比率为3.96,速动比率为3.74。该公司的市值为248.6亿美元,市盈率为44.95倍,市盈率为1.70倍,贝塔系数为1.15。Horizon Treateutics Public Limited的股价为52周低点57.84美元,52周高点为117.49美元。
Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last issued its quarterly earnings data on Wednesday, November 2nd. The biopharmaceutical company reported $1.25 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.25. The firm had revenue of $925.36 million for the quarter, compared to analyst estimates of $888.93 million. Horizon Therapeutics Public had a net margin of 15.51% and a return on equity of 24.59%. Equities research analysts predict that Horizon Therapeutics Public Limited will post 4.23 earnings per share for the current fiscal year.
Horizon Treateutics Public(纳斯达克:HZNP-GET评级)最近一次发布季度收益数据是在11月2日星期三。这家生物制药公司公布本季度每股收益为1.25美元,比普遍预期的1.00美元高出0.25美元。该公司本季度营收为9.2536亿美元,而分析师预期为8.8893亿美元。Horizon Treateutics Public的净利润率为15.51%,股本回报率为24.59%。股票研究分析师预测,Horizon Treateutics Public Limited本财年每股收益将达到4.23美元。
About Horizon Therapeutics Public
关于Horizon Treeutics Public
(Get Rating)
(获取评级)
Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.
Horizon治疗公司是一家生物制药公司,从事医药产品的研究、开发和营销。它通过孤儿节和炎症节段运作。孤儿部分由药物KRYSTEXXA、Ravicti、Procysbi、Actimmune、丁苯基、QUINSAIR和RAYOS组成。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Horizon Therapeutics Public (HZNP)
- Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
- Zimmer Biomet Beats on Earnings, Growth May be Priced In
- AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
- Ford Stock Going Forward After Big Earnings Flop
- Insiders And Institutions Buy Wolverine Worldwide
- 免费获取StockNews.com关于Horizon Treeutics Public(HZNP)的研究报告
- 细价股值得吗?你应该投资细价股吗?
- Zimmer Biomet盈利节节攀升,增长可能被计入价格
- 人工智能软件制造商EPAM号称科技板块涨幅最大
- 福特股票在盈利大幅下滑后继续前进
- 内部人士和机构收购金刚狼全球
Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.
获得《地平线治疗公共日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收Horizon Treateutics Public和相关公司的最新新闻和分析师评级的每日简要摘要。